Go back
Body SystemsProstate
Other Names
Synopsis
The Prostate: A Comprehensive Encyclopedic Reference
Overview and Definition
The prostate gland is a chestnut-shaped reproductive organ located directly beneath the urinary bladder in the male, which adds secretions to the sperm during the ejaculation of semen. The gland surrounds the urethra, the duct that serves for the passage of both urine and semen. The prostate is a six-sided organ consisting of glandular and fibromuscular tissue. It resides in the pelvic cavity and typically measures 4 × 3 × 2 cm and weighs around 20 grams. The male accessory sex glands are the prostate, the paired seminal vesicles, and the paired bulbourethral (Cowper) glands.
Anatomy and Structure
Location and Gross Anatomy
The prostate gland is a pyramid-shaped organ with an apex (in contact with the urethra and directed downward) and a base (in contact with the bladder and directed upward). The prostate lies below the urinary bladder and is located in front of the rectum. The prostate is encapsulated by both a true internal connective tissue capsule and a false external capsule, which extends from the pelvic fascia. The base of the prostate is adjacent to the neck of the urinary bladder and surrounds the prostatic urethra, which exits at the apex.
Zonal Anatomy
The prostate is composed of several zones, including the peripheral, central, and transition zones. Each zone has distinct anatomical and clinical significance:
- Peripheral Zone (PZ): This is the largest zone, comprising about 70% of the prostate. It is located at the back of the gland, near the rectum, and is where most prostate cancers originate.
- Central Zone (CZ): This zone surrounds the ejaculatory ducts and makes up about 25% of the prostate. It is relatively resistant to disease compared to the peripheral zone.
- Transition Zone (TZ): This zone surrounds the urethra and is the site where benign prostatic hyperplasia (BPH) commonly occurs. It constitutes about 5% of the prostate in young men but can grow significantly with age.
Histology
The prostate gland is a conglomerate of tubular or saclike glands that secrete fluids into the urethra and ejaculatory ducts. The secretory ducts and glands are lined with a moist, folded mucous membrane. The prostate consists of numerous small glands that secrete prostatic fluid. These glands open into ducts that converge into larger ducts, eventually emptying into the urethra.
Vasculature, Lymphatics, and Innervation
The blood from the accessory sex glands drains via the vesicoprostatic plexus to the internal iliac veins. The lymphatic drainage of the prostate involves the external iliac, internal iliac, obturator, and sacral lymph nodes. From there, lymph passes via the common iliac lymph nodes to the paracaval and paraaortic lymph nodes. The autonomic innervation reaches the prostate via the cavernous nerves and perforates together with the arterial branches the capsule of the prostate. The cavernous nerves run between the capsule of the prostate and the fascia of the levator ani muscle latero-posterior to the prostate. Parasympathetic signals stimulate glandular activity; the sympathetic innervation of α1-receptors mediates smooth muscle contraction.
Physiological Functions
Seminal Fluid Production
The primary function of the prostate is to contribute prostatic fluid to semen. The prostate contributes up to 30% of the total fluid. The remainder comes from the seminal vesicles (50% to 65%) and the testicles (5%). The prostate gland makes extra fluid in the semen. The fluid contains enzymes, zinc, and citric acid. These components help nourish sperm cells and lubricate the urethra.
Ejaculation
Muscles in the prostate also help push semen into and through the urethra when an orgasm occurs. The two ejaculatory ducts, which carry sperm and the fluid secreted by the seminal vesicles, converge and narrow in the centre of the prostate and unite with the urethra. Ejaculation is controlled by the sympathetic nervous system. The activation of prostatic alpha-receptors leads to the contraction of the smooth muscle stroma of the bladder neck.
Hormonal Dependency and Growth
Normally, the prostate reaches its mature size at puberty, between ages 10 and 14. Around age 50, the size of the prostate and the amount of its secretions commonly decrease. Hormones, especially testosterone and its conversion to dihydrotestosterone (DHT), contribute to prostate cell growth and, potentially, cancer. Males who do not secrete adequate amounts of the male hormone androgen may maintain normal function of the prostate with injections of androgen.
Urinary Flow Regulation
The urethra, a tube that carries urine and semen out of the body, passes through the prostate. Because the prostate surrounds this tube, prostate problems can affect urine flow. Enlargement of the prostate in size after midlife, often making urination difficult, may occur as a result of inflammation or malignancy.
Assessment of Prostate Health
Prostate-Specific Antigen (PSA) Testing
A prostate-specific antigen (PSA) test is a test that measures the level of PSA in the blood. PSA is a substance made mostly by the prostate that may be found in an increased amount in the blood of men who have prostate cancer. The level of PSA may also be high in men who have an infection or inflammation of the prostate or benign prostatic hyperplasia (BPH).
In prostate cancer screening, an elevated serum PSA level is the most common initial laboratory finding, as the vast majority of men with early prostate cancer are asymptomatic. PSA is a highly sensitive but relatively nonspecific and imprecise screening tool, as both benign and malignant conditions elevate the serum marker. The use of PSA screening has become controversial, with differing guidelines and recommendations regarding its application across various age groups. Despite the risks associated with serum PSA screening, including the potential for unnecessary biopsies and overdiagnosis, it remains the single most useful tool for the early detection of prostate cancer, offering patients the best chance for a cure.
The sensitivity of PSA testing ranges from 78% to 100%, while its specificity varies considerably across studies, between 6% and 66%. The Prostate Health Index (phi) is a FDA-approved blood test combining total, free, and −2proPSA with greater specificity than free and total PSA for clinically significant prostate cancer.
Digital Rectal Examination (DRE)
In a digital rectal exam (DRE), the doctor inserts a gloved, lubricated finger into the rectum and feels the rectum, anus, and prostate to check for anything abnormal. Detection of prostate cancer has traditionally been based upon digital rectal examination (DRE) and measuring serum PSA, followed by ultrasound-guided biopsy. Pre-biopsy DRE was found to add little to no diagnostic value for the routine diagnostic workflow in a constrained setting when PSA and mpMRI are the initial screening tools for patients with suspected clinically significant prostate cancer.
Multiparametric MRI (mpMRI) and Biopsy
MRI has revolutionized diagnostic precision, enabling detailed staging and targeted biopsies, but its cost and limited availability restrict widespread use. New advances have established that prostate MRI can accurately characterize focal lesions within the gland, an ability that has led to new opportunities for improved cancer detection and guidance for biopsy. MRI results are summarized using the 5-point Prostate Imaging–Reporting and Data System (PI-RADS) classification scheme.
If PSA levels continue to rise—especially if they rise quickly—or if a lump is detected during a DRE, doctors may recommend additional tests. These may include additional blood- or urine-based tests, or imaging tests, such as MRI or high-resolution micro-ultrasound. Alternatively, the doctor may recommend a prostate biopsy without further testing. During this procedure, multiple samples of prostate tissue are collected by inserting hollow needles into the prostate and then withdrawing them.
Conditions and Concerns Associated With the Prostate
Benign Prostatic Hyperplasia (BPH)
BPH is a common benign proliferative condition associated with aging in men. BPH is pathologically characterized by cellular proliferation of the epithelial and stromal elements in the prostate gland. The transition zone of the prostate surrounds the urethra and is the site where BPH commonly occurs. The prostate naturally gets bigger as men age. BPH and chronic prostatitis (CP) are common diseases in males, and BPH is often complicated by CP.
The common pathogenesis of BPH and prostate cancer (PCa) involves age, genetics, and shared risk factors such as androgens, inflammation, obesity, metabolic syndrome, and diet. A 2024 Mendelian randomization study found that BPH is a risk factor for PCa from a genetic perspective.
Prostatitis
The NIH has created four classifications for prostatitis: acute bacterial prostatitis (ABP), chronic bacterial prostatitis (CBP), chronic prostatitis/chronic pelvic pain syndrome, and asymptomatic inflammatory prostatitis. Bacterial prostatitis is relatively uncommon when compared to other causes of prostatitis. Risk factors for bacterial prostatitis include prostate manipulation, urethral stricture, BPH, phimosis, urethritis, diabetes, and other immune-compromising states, and a history of sexually transmitted infections (STIs).
Prostatitis also appears to increase the risk of developing BPH and possibly prostate cancer. A meta-analysis of 27 studies found a pooled odds ratio of 1.72 (95% CI: 1.44–2.06) for the association between prostatitis and prostate cancer.
Prostate Cancer
Prostate cancer is the second most common cancer diagnosed in men worldwide. Prostate cancer is the most common solid-organ malignancy and the second leading cause of cancer-related death among biologically male individuals in the United States. The prevalence of prostate cancer increases with age. Of all new prostate cancer cases, only 0.6% are diagnosed among men younger than 44 years of age, with the majority of cases being diagnosed at ages 65 to 74.
Risk Factors for Prostate Cancer
The etiology of prostate cancer is still largely unknown, and the only well-established risk factors are those that are non-modifiable: age, race, and family history. There are significant racial and geographical disparities in prostate cancer incidence, with African-American men experiencing both a higher incidence and more aggressive forms of the disease. Genetics also plays a pivotal role, with certain gene mutations, like BRCA1 and BRCA2, elevating risk.
Regarding modifiable risk factors, taken as a whole, findings are consistent with a small positive association (relative risks 1.3–2.0) between high-saturated-fat diets and prostate cancer incidence. Accumulating evidence indicates that obesity may have a dual effect on prostate cancer: an increased risk of aggressive PCa and a decreased risk of localized PCa. Both occupational and leisure-time physical activity have been observed to be associated with a reduced PCa risk.
Prostate Cancer and Erectile Dysfunction
Based on the anatomical and physiological interplay between the prostate and structures essential for erectile function, there is a significant association between prostate diseases (such as BPH, prostatitis, and prostate cancer) and the prevalence of erectile dysfunction (ED). The treatment modalities for prostate diseases, including surgical and pharmacological interventions, significantly influence the occurrence and severity of ED.
Nutrients, Herbs, and Natural Ingredients
Saw Palmetto (Serenoa repens)
Traditional Use
Phytotherapies used in BPH include extract of the berries of Serenoa repens (saw palmetto), among others. European physicians have used saw palmetto extract (SPE) to treat benign prostatic hyperplasia (BPH). Historically, saw palmetto berries were used by Native American peoples of the Southeastern United States for food and urinary tract symptoms, with phytomedicinal use in European markets developing from the late 20th century onwards.
Scientific Evidence
Extract of the berries of the saw palmetto or the American dwarf palm tree (Serenoa repens) has been the best studied of the phytotherapies for BPH. Although several small studies have suggested modest benefit of saw palmetto for treating symptoms of BPH, a large study evaluating high doses of saw palmetto and a Cochrane review found that saw palmetto was not more effective than placebo for treatment of urinary symptoms related to BPH.
The CAMUS trial was a large, randomized, double-blind, placebo-controlled, multicenter North American trial. In this trial, 369 men older than 45 years with an AUA symptom score of 8 to 24 were randomly assigned to placebo or dose escalation of saw palmetto (320 mg for the first 24 weeks, 640 mg for the next 24 weeks). The trial found that saw palmetto extract does not affect serum prostate-specific antigen more than placebo, even at relatively high doses.
One smaller double-blind, placebo-controlled trial (n=44) found that the saw palmetto herbal blend and placebo groups had improved clinical parameters with a slight advantage in the saw palmetto group, which was not statistically significant. Neither PSA nor prostate volume changed from baseline. A subsequent trial of phytosterol-enriched saw palmetto oil found a significant increment in the maximum and average urine flow rate in subjects treated with enriched saw palmetto oil as compared to placebo. Overall, the evidence for saw palmetto as a monotherapy for BPH urinary symptoms is currently considered insufficient to support its routine use based on large, high-quality trials.
Pygeum (Pygeum africanum / Prunus africana)
Traditional Use
Pygeum africanum, also known as the African plum tree, is an evergreen tree native to central and southern African mountains, Madagascar, the Comoros islands, and the Gulf of Guinea. Extracts from the bark of the tree have traditionally been used for inflammation, kidney diseases, urinary problems, prostate gland inflammation, and other uses.
Scientific Evidence
Compared to men receiving placebo, Pygeum africanum provided a moderately large improvement in the combined outcome of urologic symptoms and flow measures. A 2002 meta-analysis indicated that Pygeum africanum is more effective than placebo in relieving BPH-related symptoms. A 2002 Cochrane review of 18 randomized controlled trials involving 1,562 men with BPH concluded that a standardized preparation may be a useful treatment option for men with lower urinary symptoms consistent with BPH. However, the studies included in the review were small in size, were of short duration, and used varied doses and preparations of the extract. Clinical studies have concluded that Pygeum africanum is generally well-tolerated, with mild adverse effects such as diarrhea, nausea, constipation, and headache. The overall evidence is characterized as limited and preliminary.
Stinging Nettle Root (Urtica dioica)
Traditional Use
Stinging nettle root has a long history of use in European herbal medicine, where the root preparations were traditionally applied to support urinary function in men with lower urinary tract symptoms. Nettle root is more commonly studied in combination with other prostate botanicals, particularly saw palmetto or pygeum, rather than on its own.
Scientific Evidence
A randomized, double-blind study gave men 600 mg of nettle root daily (split into two doses) for eight weeks and found improvements in urinary symptoms. Several other controlled trials have been conducted, generally of short duration and small sample sizes. Findings from one study suggest that a combination therapy of saw palmetto, lycopene, selenium, and tamsulosin is more effective than single therapies in improving the International Prostate Symptom Score and increasing maximum urinary flow rate. Evidence for nettle root as a standalone agent is limited; larger, well-powered trials are lacking.
Lycopene
Traditional Use
Lycopene has no specific formal history in traditional herbal medicine as an isolated compound. Its associations with prostate health derive from epidemiological observations of tomato-rich diets in Mediterranean and other cultures. Lycopene is a phytochemical that belongs to a group of pigments known as carotenoids. It is red, lipophilic, and naturally occurring in many fruits and vegetables, with tomatoes and tomato-based products containing the highest concentrations of bioavailable lycopene.
Scientific Evidence
Several epidemiological studies have linked increased lycopene consumption with decreased prostate cancer risk. These findings are supported by in vitro and in vivo experiments showing that lycopene not only enhances the antioxidant response of prostate cells, but that it is even able to inhibit proliferation, induce apoptosis, and decrease the metastatic capacity of prostate cancer cells. However, there is still no clearly proven clinical evidence supporting the use of lycopene in the prevention or treatment of prostate cancer, due to the only limited number of published randomized clinical trials and the varying quality of existing studies. Evidence remains preliminary, primarily epidemiological and preclinical.
Selenium
Traditional and Background Use
Selenium is an essential dietary trace mineral found in soil and foods including Brazil nuts, seafood, and grains. Interest in selenium for prostate health arose from observational data showing that men in selenium-replete regions had lower rates of prostate cancer. Studies demonstrated that supplemental selenium selectively accumulated in the prostate, providing additional biological plausibility for chemopreventive effects of selenium against prostate cancer.
Scientific Evidence
The most authoritative evidence comes from the Selenium and Vitamin E Cancer Prevention Trial (SELECT). SELECT was conducted to assess the efficacy of selenium and vitamin E alone, and in combination, on the incidence of prostate cancer. This randomized, double-blind, placebo-controlled, 2 × 2 factorial design clinical trial found that neither selenium nor vitamin E reduced the incidence of prostate cancer after seven years, and that vitamin E was associated with a 17% increased risk of prostate cancer compared to placebo. Beginning in 2001, a total of 35,533 men aged 50 to 55 years and older were enrolled in this double-blind, randomized, controlled trial. The trial was terminated early. The null result was surprising given the strong preclinical and clinical evidence suggesting chemopreventive activity of selenium. It is likely that only specific subpopulations may benefit from selenium supplementation; therefore, future studies should consider the baseline selenium status of the participants, age of the cohort, and genotype of specific selenoproteins.
Vitamin E
Scientific Evidence
The SELECT trial also specifically addressed vitamin E supplementation. Hazard ratios found a significant increase (HR 1.17, 99% CI 1.004–1.36) for prostate cancer risk in the vitamin E group. Dietary supplementation with vitamin E significantly increases the risk of prostate cancer among healthy men. While various formulations of selenium and vitamin E, both essential human dietary components, have been shown to possess a therapeutic and preventive effect against prostate cancer in some preclinical settings, the SELECT trial results represent high-level clinical evidence against the use of supplemental vitamin E for prostate cancer prevention in healthy men.
Beta-Sitosterol
Traditional and Background Use
Beta-sitosterol is a phytosterol found in saw palmetto and many other plant sources, including rice bran, wheat germ, corn oils, soybeans, avocados, pecans, and peanuts, and has its own body of clinical evidence for BPH symptoms.
Scientific Evidence
Phytoconstituents such as sterols, fatty acids, and vitamin E together contribute to the efficacy of saw palmetto extract in mitigating BPH complications. Clinical trials with isolated beta-sitosterol have reported improvements in urinary symptom scores and flow parameters versus placebo. However, many of these trials have been of short duration and modest scale, and the results are not consistently replicated in independent large trials.
Zinc
Background
Prostatic fluid contains enzymes, zinc, and citric acid. These components help nourish sperm cells and lubricate the urethra. The prostate gland contains one of the highest zinc concentrations of any soft tissue in the human body. Zinc is involved in regulating cell proliferation and apoptosis in prostate cells, and reductions in prostate zinc content have been observed in prostate cancer tissue in laboratory studies. Clinical evidence for zinc supplementation as a preventive or therapeutic agent for prostate conditions remains very limited, and no authoritative body currently recommends supplemental zinc specifically for prostate health outcomes.
Pumpkin Seed (Cucurbita pepo)
Traditional Use
Pumpkin seed preparations have been used in Central and Eastern European folk medicine, particularly for urinary tract complaints and BPH-associated lower urinary tract symptoms (LUTS).
Scientific Evidence
Pumpkin seed is listed among the phytotherapies used in BPH in an NIH-published review of nutraceuticals in prostate disease. A small number of randomized controlled trials have reported modest improvements in IPSS scores and quality of life, but the evidence base is limited in scale and methodological quality. Independent replication in large, high-quality trials is lacking.
Rye Pollen Extract (Cernilton)
Traditional and Background Use
Rye pollen (also known under the brand name Cernilton) is among the phytotherapies used in BPH. Cernilton has been studied primarily in Europe and Japan for both BPH and chronic prostatitis.
Scientific Evidence
Several small randomized trials have examined rye pollen extract for BPH and chronic prostatitis/chronic pelvic pain syndrome (CPPS), reporting reductions in symptom scores. However, these trials are generally limited in size and duration, and evidence from large, independent, well-powered trials is lacking.
Lifestyle and Dietary Factors Supporting Prostate Function
The prevention of lethal prostate cancer is a critical public health challenge. Evidence summarizes selected behavioral risk factors including obesity and weight change, physical activity, smoking, antioxidant intake, vitamin D and calcium, and coffee intake.
Dietary habits and lifestyle choices influence susceptibility, with diets low in fruits and vegetables and high in saturated fats linked to higher risk. International variation in the risk of prostate cancer is profound, as is the frequency with which migrants from low- to high-risk areas adopt the risk pattern of the host country, possibly within a single generation, suggesting that modifiable lifestyle and dietary factors are genuinely important. Both occupational and leisure-time physical activity have been observed to be associated with a reduced PCa risk. None of the botanical supplements are officially recommended by the American Urological Association or the European Association of Urology, and they are best understood as complementary options rather than replacements for medical treatment.
References
- Urology-Textbook.com — Prostate Gland: Anatomy, Histology and Function
- Encyclopaedia Britannica — Prostate Gland: Anatomy & Function
- Cleveland Clinic — Prostate: Anatomy, Location, Function & Conditions
- Medical News Today — Prostate: Functions, diseases, structure, and tests
- Kenhub — Prostate: Anatomy, Histology and Function
- NIH/StatPearls — Prostate-Specific Antigen (PSA)
- PMC — The Prostate Health Index: Its Utility In Prostate Cancer Detection
- NCI — Prostate Cancer Screening (PDQ)
- NIH/NCBI — Prostate Cancer Screening (PDQ): Health Professional Version
- PMC — Evaluating prostate cancer diagnostic methods: The role and relevance of digital rectal examination
- PMC — Prostate Cancer Detection and Diagnosis: The Role of MR
- NCI — Prostate-Specific Antigen (PSA) Test Fact Sheet
- NIH/StatPearls — Acute Bacterial Prostatitis
- PMC — Correlation between Prostatitis, Benign Prostatic Hyperplasia and Prostate Cancer: A Systematic Review and Meta-Analysis
- PMC — Causal Relationship Between Prostatic Diseases and Prostate Cancer: A Mendelian Randomization Study
- PMC — The Role of Prostatitis in Prostate Cancer: Meta-Analysis
- PMC — Nutraceuticals in Prostate Disease: The Urologist's Role
- NCCIH — Benign Prostatic Hyperplasia and Complementary and Integrative Approaches: What the Science Says
- PubMed — Effect of Increasing Doses of Saw Palmetto on PSA: Analysis of the CAMUS Randomized Trial
- PMC — A Double-Blind, Placebo-Controlled Randomized Comparative Study on Phytosterol-Enriched and Conventional Saw Palmetto Oil in BPH
- PMC — Pygeum africanum for Benign Prostatic Hyperplasia (Cochrane Review)
- PMC — The Potential Role of Lycopene for the Prevention and Therapy of Prostate Cancer
- PMC — Selenium and Prostate Cancer Prevention: Insights from SELECT
- PMC — Vitamin E and the Risk of Prostate Cancer: Updated Results of SELECT
- PMC — Risk Factors for Prostate Cancer
- PMC — Lifestyle and Dietary Factors in the Prevention of Lethal Prostate Cancer
- PMC — An In-Depth Look Into the Epidemiological and Etiological Aspects of Prostate Cancer
- Wiley Online Library — Phytotherapy of Benign Prostatic Hyperplasia: A Minireview
Natural Remedies
Ingredients
These ingredients are often used in alternative medicine to support prostate.
- astaxanthinScientific
Astaxanthin, a ketocarotenoid from Haematococcus pluvialis, has emerging evidence for prostate health. A 2019 nutraceutical review (PubMed PMID 31577095) specifically cited astaxanthin alongside zinc as producing BPH symptom effects comparable to the clinically validated Serenoa repens/lycopene/selenium combination. Preclinical studies show astaxanthin inhibits growth and induces apoptosis in LNCaP and PC-3 prostate cancer cell lines.
- bee pollenScientific
Standardized bee pollen extracts (Cernilton, Graminex, Pule'an) have the most robust clinical evidence of any bee pollen application. Multiple RCTs and a Cochrane review support modest improvement in BPH urinary symptoms and clinical evidence for chronic prostatitis treatment.
- beta and delta tocopherolsScientific
Non-alpha tocopherols including delta-tocopherol have demonstrated anti-proliferative activity against prostate cancer cells through multiple mechanisms. Observational human studies show inverse associations between plasma non-alpha tocopherol levels and prostate cancer risk. Cell studies confirm that delta-tocopherol combined with gamma-tocopherol induces cell cycle arrest in androgen-dependent prostate cancer cells.
- beta-sitosterolScientific
Beta-sitosterol, a phytosterol found in many plants, demonstrated significant improvements in BPH-related LUTS in multiple placebo-controlled RCTs and a Cochrane systematic review. Proposed mechanisms include 5α-reductase inhibition, anti-inflammatory activity, and pro-apoptotic effects on prostate epithelial cells. A Cochrane review found beta-sitosterol improved symptom scores and urinary flow in men with mild-to-moderate BPH.
- boronScientific
Boron has epidemiological and preclinical evidence for prostate cancer risk reduction. One large observational study found men with the highest boron intake had approximately 54–64% lower prostate cancer risk vs. those with the lowest intake. Animal studies found boron supplementation reduced PSA levels by 86–89% and inhibited LNCaP prostate tumor growth by inhibiting IGF-1 expression. Boron also appears in clinical combination prostate supplement studies.
- brassicasterolScientific
In vitro evidence from a peer-reviewed study demonstrates that brassicasterol specifically targets prostate cancer cell signaling, downregulating androgen receptor (AR) expression, reducing PSA levels, inducing apoptosis, and inhibiting cell migration in LNCaP prostate cancer cells. The compound acts via dual inhibition of AKT and AR pathways. Evidence is confined to in vitro cell models; no human or animal in vivo studies have been conducted.
- campesterolScientific
Campesterol inhibits 5α-reductase type 2 (S5αR2) in vitro—the prostate-expressed enzyme converting testosterone to DHT, the primary androgen driving prostatic cell proliferation. Campesterol is a component of saw palmetto extracts and phytosterol blends studied in BPH clinical trials. These findings provide a direct mechanistic rationale for campesterol's prostate interaction.
- cauliflowerScientific
Prospective epidemiological studies link high cauliflower consumption to reduced aggressive prostate cancer risk. I3C, DIM, and sulforaphane from cauliflower inhibit prostate cancer cell proliferation, suppress androgen signaling, induce apoptosis, and have shown PSA reduction in phase I clinical trials.
- citrus pectinScientific
Modified citrus pectin has the most clinical evidence among natural compounds for prostate cancer management, via galectin-3 inhibition. Two Phase II human trials demonstrate MCP slows PSA doubling time in biochemically relapsed prostate cancer patients, with 75% of patients achieving PSADT improvement at 6 months on 4.8 g three times daily.
- cranberryScientific
Cranberry has been included in a prospective multicenter open-label clinical pilot study (Advances in Urology 2020, PMC 7083134) in combination with pumpkin seed extract and soy isoflavonoids for BPH/LUTS, showing significant IPSS improvements at 1 and 3 months. Cranberry proanthocyanidins also reduce urinary tract infection risk—a significant BPH comorbidity—and a 2020 review listed cranberry extracts among supplements examined in prostate cancer RCTs.
- cucurbitaScientific
Cucurbita pepo (pumpkin) seed oil and extract are approved by the German Commission E and ESCOP for BPH-related voiding difficulties. Several RCTs showed improvements in IPSS and urinary flow in men with mild-to-moderate BPH. A 2021 single-blind RCT (BMC Urology) compared pumpkin seed oil directly to tamsulosin in BPH patients; pumpkin seed oil reduced symptoms with no side effects, though less effectively than tamsulosin.
- curcuminScientific
Curcumin, the primary bioactive of turmeric, has clinical evidence for BPH and prostatitis when used in combination formulas. A 2019 nutraceutical review (PubMed PMID 31577095) cited clinical evidence for curcumin's efficacy on BPH symptom scores. Multiple preclinical studies and the Anticancer Research 2019 systematic review identify curcumin as a prostate cancer chemopreventive agent via AR, NF-κB, and VEGF pathway modulation.
- daidzeinScientific
Daidzein, a soy isoflavone, has evidence for prostate health via inhibition of prostate smooth muscle contraction (relevant to BPH/LUTS), prostate cancer antiproliferative activity, and as a precursor to the more potent equol. A 2022 in vitro study (Nutrients) found daidzein reduced prostate stromal cell viability by 62% and inhibited alpha-1-adrenergic and neurogenic prostate smooth muscle contractions, providing mechanistic support for inverse relationships between soy nutrition and BPH.
- delta-tocopherolScientific
Delta-tocopherol exerts potent anti-proliferative and pro-apoptotic effects specifically in prostate gland tissue and prostate cancer cells, acting via suppression of androgen receptor signaling and PSA expression. It is consistently more active than α-tocopherol in prostate cancer cell lines and xenograft models. This represents one of the most thoroughly studied organ-specific activities of δ-tocopherol.
- DIM (diindolylmethane)Scientific
DIM (3,3'-diindolylmethane), the principal metabolite of indole-3-carbinol from cruciferous vegetables, has documented antiproliferative and pro-apoptotic activity in prostate cancer cells via androgen receptor downregulation, Akt and NF-κB inhibition, and HDAC inhibition. It is cited in a 2021 systematic review of phytotherapeutics for biochemically recurrent prostate cancer and in the Anticancer Research 2019 prostate cancer prevention review.
- EGCG (epigallocatechin gallate)Scientific
EGCG, the principal catechin of green tea, has robust preclinical and compelling Phase II clinical evidence for prostate cancer chemoprevention. An Italian double-blind, placebo-controlled RCT (Cancer Res 2006, n=60 men with HGPIN) found only 3.3% of catechin-treated men developed prostate cancer vs. 30% of placebo-treated men over 12 months. The Anticancer Research 2019 systematic review identified EGCG as a key micronutrient for prostate cancer prevention.
- equolScientific
Equol, a gut metabolite of the soy isoflavone daidzein, has been cited in a 2019 authoritative nutraceutical review (PubMed PMID 31577095) as having demonstrated clinical efficacy on BPH symptoms alongside quercetin and curcumin. Equol directly binds and sequesters DHT, and clinical RCTs have shown it reduces prostate volume and LUTS in BPH patients, particularly in equol non-producers supplemented directly with equol.
- flaxseedScientific
Flaxseed, the richest plant source of secoisolariciresinol diglucoside (SDG) lignan, has clinical evidence from two RCTs in prostate cancer pre-surgical settings. Demark-Wahnefried et al. (Cancer Epidemiol Biomarkers Prev 2008, n=161, randomized, 30 g/day flaxseed) found significant reductions in prostate tumor proliferation (Ki-67) and total testosterone. Flaxseed is listed among recognized alternative medications for BPH/prostate in urological literature.
- gamma tocopherolScientific
Gamma-tocopherol demonstrates anti-proliferative and pro-apoptotic effects in prostate cancer cell lines and animal models. The landmark Johns Hopkins nested case-control study found high serum γT strongly associated with reduced prostate cancer risk. Human evidence remains inconsistent across studies, with the PLCO trial showing a non-significant trend toward elevated risk.
- ganodermaScientific
Ganoderma lucidum triterpenes inhibit 5α-reductase and prostate cancer cell growth, and a clinical trial found a significant reduction in prostate volume. Preclinical cell-line data confirm anti-proliferative and pro-apoptotic effects in both BPH and prostate cancer models.
- genisteinScientific
Genistein, the predominant soy isoflavone, has extensive preclinical and emerging clinical evidence for prostate cancer prevention. Higher genistein intake in Asian populations correlates epidemiologically with lower prostate cancer rates. A Phase II clinical trial incorporated genistein (20 mg/day) in a prostate health cocktail with PSA stabilization outcomes. A comprehensive review (Prostate Cancer Prostatic Dis 2007) extensively reviewed its mechanisms and clinical data.
- glutamic acidScientific
Glutamate metabolism is relevant to the prostate gland both in benign enlargement and malignancy. A clinical placebo-controlled trial demonstrated that a combination including glutamic acid reduced urinary symptoms in BPH. Metabolomic and Mendelian randomization studies have identified an inverse association between serum glutamate and prostate cancer risk.
- green teaScientific
Green tea and its polyphenols (predominantly EGCG) have been studied in clinical trials for prostate cancer prevention. A 2006 Italian RCT (n=60, HGPIN) showed a ~10-fold lower conversion to prostate cancer with green tea catechin supplementation vs. placebo over 12 months. Green tea catechins were also documented in pre-surgical trials to reduce PSA and VEGF in prostate cancer patients, and the Anticancer Research 2019 systematic review included green tea as a chemopreventive agent.
- HMR (7-hydroxymatairesinol)Scientific
Dietary HMR inhibited LNCaP human prostate cancer xenograft growth in athymic mice, reducing tumor volume, take rate, and cell proliferation while increasing apoptosis. ENL, HMR's metabolite, also induces apoptosis in LNCaP cells via mitochondrial caspase pathways in vitro. Epidemiological data associate higher enterolactone levels with reduced prostate cancer risk.
- HMR lignanScientific
HMR is the only purified dietary lignan tested in an animal prostate cancer model, demonstrating significant inhibition of LNCaP xenograft tumor growth. Enterolactone, the human metabolite, induces mitochondrial apoptosis in human prostate cancer cell lines. Inconsistent epidemiological data limit confirmation at the population level.
- hydroxymatairesinolScientific
Dietary HMR inhibited LNCaP human prostate cancer xenograft growth in athymic mice, increasing apoptosis and reducing tumor volume and take rates. Mechanistically, HMR converts to enterolactone, which inhibits aromatase—relevant to prostatic estrogen-androgen balance. A US patent identifies HMR as potentially beneficial for BPH and prostate cancer prevention. No human prostate-specific RCTs have been completed.
- indole-3-carbinolScientific
Indole-3-carbinol (I3C), found in cruciferous vegetables, and its metabolite DIM have clinical and preclinical evidence for prostate cancer chemoprevention. The Anticancer Research 2019 systematic review identified I3C among key micronutrients for prostate cancer prevention. I3C modulates androgen and estrogen metabolism, targets cancer stem cells, and inhibits epigenetic alterations in prostate cancer cells.
- L-alanineScientific
L-Alanine has been investigated as part of a three-amino-acid combination (with glycine and glutamic acid) for reducing prostate enlargement and lower urinary tract symptoms in BPH. Clinical reports dating to 1958 reported prostate size reduction and urinary symptom improvement with this combination.
- lignansScientific
The prostate is a hormonally sensitive gland influenced by lignan enterometabolites through multiple mechanisms: sex hormone balance modulation, 5-alpha-reductase inhibition, anti-inflammatory NF-κB inhibition, and support of a gut microbiome associated with healthier hormonal regulation. Epidemiological meta-analyses and a clinical pre-surgery trial provide human-level evidence.
- lycopeneScientific
Lycopene, the red carotenoid abundant in tomatoes, has been studied extensively for prostate cancer risk reduction and BPH. A systematic review and meta-analysis (Chen et al., Medicine 2015, 26 studies) found an inverse association between lycopene intake and prostate cancer risk. Combined with Serenoa repens and selenium in a 224-patient Italian RCT, lycopene significantly improved BPH IPSS scores vs. individual agents. A pre-surgical RCT found lycopene reduced PSA and tumor volume in localized prostate cancer.
- macaScientific
Red maca specifically and consistently reduces prostate size in animal models of BPH, through a mechanism downstream of DHT conversion, without affecting serum testosterone or seminal vesicle weight. Traditional use by older Andean men for prostate support is also documented.
- mangosteenScientific
Mangosteen xanthones have been identified for anti-inflammatory effects in prostatic hyperplasia models. A review of mangosteen's anti-inflammatory potency specifically lists prostatic hyperplasia among the conditions where xanthone activity has been studied. Evidence is preclinical only.
- milk thistleScientific
Milk thistle (Silybum marianum) and its principal constituent silybin have preclinical and Phase I/II clinical evidence for prostate cancer. A systematic review of phytotherapeutics for biochemically recurrent prostate cancer (PMC 8631186, 2021) identified silymarin as an agent with preclinical and clinical evidence. A Phase I/II clinical trial (Flaig et al., Prostate 2010) found silybin-phytosome accumulated in prostatic tissue with acceptable safety and PSA stabilization signals.
- myristoleateScientific
Myristoleic acid, the free acid moiety of cetyl myristoleate, has been identified as the cytotoxic component in saw palmetto extract that induces apoptosis and necrosis in human prostate cancer LNCaP cells (Iguchi et al., Prostate, 2001). This is in vitro evidence from the free acid form only; no human clinical trials of CMO for prostate conditions have been conducted.
- nettleScientific
Stinging nettle (Urtica dioica) root extract has been studied in multiple RCTs for BPH and is approved by the German Commission E (4–6 g/day) for urinary complaints associated with BPH. A 2022 systematic review of 6 RCTs (n=1,210 BPH patients) found Urtica dioica modestly improved IPSS scores vs. controls. Mechanisms include sex hormone-binding globulin (SHBG) binding inhibition and anti-inflammatory activity in prostate tissue.
- phytosterolsScientific
The prostate is the primary body system target for phytosterols in men. Beta-sitosterol has multiple RCTs demonstrating improvement in BPH symptoms including IPSS scores, peak urinary flow, and post-void residual volume. Mechanistic evidence shows direct inhibition of prostate smooth muscle contraction and stromal cell growth.
- pineScientific
A clinical study in 75 men with benign prostatic hyperplasia (BPH) using Pycnogenol 50 mg three times daily for 60 days showed significant improvement in all urinary symptom domains compared to standard management and 5-alpha reductase inhibitor therapy (P<0.05). This is the primary clinical evidence specific to the prostate from authorized medical databases.
- pine barkScientific
Clinical studies including a controlled trial demonstrate Pycnogenol reduces BPH urinary symptoms and is listed among herbal remedies studied for BPH. The 2018 PubMed review confirms prostate symptom reduction in double-blind studies. Anti-inflammatory mechanisms in prostatic tissue are proposed as the basis.
- piperineScientific
Piperine, the principal alkaloid of black pepper, is identified in the Anticancer Research 2019 systematic review among dietary micronutrients with evidence for prostate cancer prevention. It inhibits androgen receptor signaling, induces apoptosis, and inhibits PI3K/Akt pathway in prostate cancer cells. Piperine also substantially enhances bioavailability of prostate-relevant agents such as curcumin by up to 2,000%.
- plant sterolsScientific
Beta-sitosterol, the dominant plant sterol in phytosterol supplements, has well-documented activity in the prostate. Multiple RCTs confirm improvements in lower urinary tract symptoms and urinary flow in men with BPH. Proposed mechanisms include inhibition of 5-alpha-reductase, anti-inflammatory effects on prostate tissue, and direct inhibition of prostate smooth muscle contraction.
- pomegranateScientific
Pomegranate juice and extracts have been tested in Phase II clinical trials for men with rising PSA after prostate cancer treatment. The landmark Phase II study (Pantuck et al., Clin Cancer Res 2006, n=46) found mean PSA doubling time increased from 15.4 to 54.0 months with 8 oz pomegranate juice daily. Multiple in vitro studies document anti-proliferative and pro-apoptotic activity against prostate cancer cell lines via punicalagin, ellagic acid, and other polyphenols.
- prunusScientific
The prostate is the primary target organ of Prunus africana (pygeum) bark extract, with the strongest herbal clinical evidence base for this organ. Phytosterols, ferulic acid esters, and triterpenes collectively reduce prostatic inflammation, inhibit androgenic proliferation, and block cholesterol accumulation in prostate tissue. In-vitro and in-vivo studies also show antiandrogenic and antiangiogenic effects relevant to prostate cancer, though clinical cancer trials are lacking.
- pumpkinScientific
Pumpkin seed oil is one of the most clinically studied herbal interventions for benign prostatic hyperplasia. Multiple human RCTs demonstrate meaningful reductions in International Prostate Symptom Score, improved urinary flow, and quality-of-life benefits. Delta-7 phytosterols inhibit 5-alpha reductase, and zinc supports prostate tissue function.
- punicalaginsScientific
Punicalagins are the principal ellagitannin polyphenols of pomegranate, responsible for >50% of its antioxidant activity and identified as the key bioactive constituents in pomegranate's prostate cancer clinical activity. They have anti-proliferative and pro-apoptotic activity in prostate cancer cell lines and their content in pomegranate products was shown to be critical for clinical efficacy in PSA doubling time studies.
- pygeumScientific
Pygeum (Prunus africanum/Pygeum africanum) bark extract is a well-established European phytotherapy for BPH. A Cochrane systematic review of 18 RCTs (n=1,562 men; 30–122 days) found men using Pygeum were more than twice as likely to report overall symptom improvement vs. placebo, with peak urine flow increased by 23%. Proposed mechanisms include inhibition of prostatic fibroblast proliferation and anti-inflammatory prostaglandin suppression.
- quercetinScientific
Quercetin, a dietary flavonoid polyphenol, has clinical evidence for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). A double-blind, placebo-controlled RCT (Urology 1999, n=30) found significant improvement in CP/CPPS symptom scores with 500 mg quercetin twice daily vs. placebo. It also appears in systematic reviews for prostate cancer chemoprevention and BPH polyphenol therapy.
- reishi mushroomScientific
Reishi mushroom (Ganoderma lucidum) has been identified in a systematic review of phytotherapeutic interventions for biochemically recurrent prostate cancer (PMC 8631186, 2021) as having preclinical and clinical evidence. It is among dietary supplements examined in RCTs for PSA-related outcomes (PubMed PMID 33003518, 2020). Mechanisms include 5α-reductase inhibition, androgen receptor suppression, and immunomodulation via beta-glucans.
- resveratrolScientific
Resveratrol, a polyphenol stilbene from grape skins and other plants, has preclinical and emerging clinical evidence for prostate cancer. A 2021 systematic review of phytotherapeutic interventions for biochemically recurrent prostate cancer (PMC 8631186) identified resveratrol as having preclinical and clinical evidence. The Anticancer Research 2019 systematic review also listed resveratrol among agents with molecular and epidemiological evidence for prostate cancer prevention.
- ryeScientific
Multiple small clinical trials demonstrate that whole-grain and bran rye consumption reduces PSA levels and modulates tumor-relevant biomarkers in men with prostate cancer. Rye lignans, benzoxazinoids, and fiber-mediated insulin reduction are the proposed mechanisms. Evidence is promising but limited to small RCTs requiring confirmation in larger trials.
- saw palmettoScientific
Saw palmetto (Serenoa repens) lipid-sterol extract is one of the most extensively studied phytotherapeutics for BPH. Multiple RCTs and meta-analyses support reductions in lower urinary tract symptoms, though the large CAMUS trial (JAMA 2011, n=369) found no significant benefit over placebo at escalating doses. Mechanisms include partial 5α-reductase inhibition and anti-inflammatory activity. The German Commission E and ESCOP recognize it for BPH-related voiding complaints.
- secoisolariciresinol diglucosideScientific
SDG and its metabolite enterolactone suppress prostate stromal cell proliferation via the GPER/ERK/p53/p21 pathway, significantly reducing prostate enlargement in BPH animal models. Dietary SDG at 600 mg/day has been reported to reduce urinary tract symptoms in BPH subjects. ERβ, expressed in the prostate, is the relevant receptor for SDG's weak phytoestrogenic action in this tissue.
- seleniumScientific
Selenium is an essential trace mineral with documented relevance to prostate biology. The NPC trial (JAMA 1996, n=1,312) reported a 63% reduction in prostate cancer incidence as a secondary endpoint with 200 mcg/day selenized yeast; however, the large SELECT trial (JAMA 2009, n=35,533) found no significant reduction in prostate cancer incidence with L-selenomethionine. A 2023 PMC review identifies selenium's roles in AR signaling, antioxidant defense, and apoptosis regulation in prostate tissue.
- soyScientific
Soy isoflavones interact directly with prostate tissue via ERβ and androgen receptor pathways. Epidemiological and Phase II clinical data support isoflavone effects on PSA levels and prostate cell biology. Equol-producing status is a key determinant of isoflavone activity in prostate tissue.
- soy isoflavonesScientific
Soy isoflavones (predominantly genistein and daidzein) have been studied in clinical trials for prostate cancer prevention and BPH. A 2018 updated systematic review and meta-analysis confirmed a protective association between soy/isoflavone consumption and prostate cancer risk. A Phase II trial (PMC 4234307) used soy isoflavones as part of a prostate health cocktail in biochemically recurrent prostate cancer patients, documenting PSA stabilization.
- soybeanScientific
Population studies associate higher soy isoflavone consumption with reduced prostate cancer risk. Soy isoflavones modulate androgen receptor activity, inhibit androgen-dependent gene expression in prostate tissue, and alter cell cycle and apoptosis pathways in prostate cells. Clinical trials show inconsistent effects on PSA levels, and most RCTs find no significant PSA-lowering effect.
- sulforaphaneScientific
Sulforaphane, an isothiocyanate from cruciferous vegetables, has evidence from molecular, preclinical, and emerging clinical studies for prostate cancer prevention. The Anticancer Research 2019 systematic review identified sulforaphane as a key micronutrient with prostate cancer prevention evidence. It induces G2/M cell cycle arrest, activates Nrf2/ARE pathway, produces HDAC inhibition, and disrupts androgen receptor signaling in prostate cancer cells.
- tomatoScientific
Tomato and lycopene accumulate in prostate tissue and have been extensively studied for prostate cancer prevention and management. Epidemiological meta-analyses show modest risk reduction with cooked tomato intake. Lycopene reduces oxidative DNA damage, inhibits prostate cell proliferation, and modulates androgen metabolism in the prostate.
- turkey tail mushroomScientific
Turkey tail mushroom (Trametes versicolor/Coriolus versicolor) has been cited in a systematic review of phytotherapeutic interventions for biochemically recurrent prostate cancer (PMC 8631186, 2021) as having preclinical and clinical evidence. Its polysaccharide-K (PSK) and polysaccharopeptide (PSP) constituents show immunomodulatory and anti-invasive activity relevant to prostate cancer management.
- watermelonScientific
Lycopene, abundant in watermelon, accumulates in prostate tissue and has been associated with reduced prostate cancer risk in multiple epidemiological studies. In vitro evidence confirms lycopene induces apoptosis and cell cycle arrest in prostate carcinoma cells.
- zincScientific
Zinc is uniquely concentrated in normal prostate tissue—the highest of any soft tissue—and this concentration is markedly reduced in prostate cancer. Multiple epidemiological and laboratory studies document zinc's antiproliferative and pro-apoptotic effects in prostate cancer cells. A 2019 Anticancer Research systematic review identified zinc as a key micronutrient for prostate cancer prevention, and a 2019 nutraceutical review cited clinical evidence for zinc in BPH symptom management.
- buchuTraditional
The prostate is one of buchu's most consistently cited traditional organ targets, with use for prostatitis and BPH documented in South African, European, and American herbal medicine. Mechanistic preclinical data support anti-inflammatory and diuretic actions relevant to prostate health. No clinical trials in prostate disease patients have been conducted.
- cornTraditional
Corn silk is traditionally used for prostatitis and BPH across multiple medical traditions. A peer-reviewed rat study demonstrated that corn silk extract (maysin) significantly reduced prostate weight, DHT, PSA, and 5α-reductase 2 expression in testosterone-induced BPH. No human clinical trials have been conducted.
- cornsilkTraditional
Corn silk has a well-documented traditional application for prostate conditions including prostatitis and benign prostatic hyperplasia, used to soothe urinary tract mucosa and reduce prostate inflammation. No human clinical trials for prostate-specific endpoints have been published.
- garlicTraditional
Garlic has traditional and early clinical associations with prostate health, including reduced prostate cancer risk in epidemiological data and preliminary clinical evidence for benign prostatic hyperplasia (BPH). RxList notes early research suggesting liquid garlic extract reduced prostate mass and urinary frequency in BPH, though evidence quality is considered limited.
- goldenrodTraditional
Goldenrod has traditional use for prostatic conditions, documented in European phytotherapy texts, German Commission E records, and complementary medicine databases. Traditional indications include prostatic hypertrophy and associated urinary difficulty. A preclinical study showed S. virgaurea extract suppressed prostate tumor cell growth in a mouse model. Clinical prostate-specific trials are absent.
- gravel rootTraditional
Gravel root appears in traditional herbal practice for prostatitis and urinary symptoms linked to prostate conditions, utilized as a urinary anti-inflammatory and diuretic. No clinical trial evidence supports this application.
- greek mountain teaTraditional
GMT's traditional use for prostatic hyperplasia (enlarged prostate) is specifically listed in the 2023 Herba Sideritis systematic monograph and multiple peer-reviewed ethnobotanical reviews. No preclinical mechanistic studies or human clinical trials on prostate health using GMT have been identified in the literature.
- hydrangeaTraditional
The prostate is a documented traditional target of hydrangea root use in North American folk medicine and TCM, for conditions including prostatitis and BPH. WebMD, RxList, and Healthline all document this traditional use. The diuretic and anti-inflammatory properties are the proposed mechanistic basis. No human studies have been conducted.
- nopalTraditional
In vitro (test-tube) studies indicate that nopal cactus flowers may have activity relevant to benign prostatic hyperplasia (BPH). Traditional ethnomedicine documents nopal for prostatosis. No human clinical trials evaluating nopal for prostate health have been identified. Evidence is preclinical and traditional.
- nut grassTraditional
Ethnobotanical use of C. rotundus for prostatitis is documented in the PubMed 2015 review. The antiandrogenic property of C. rotundus is pharmacologically relevant to androgen-driven prostate conditions. Antimicrobial properties are relevant to bacterial prostatitis.
- prickly pear cactusTraditional
Traditional use of prickly pear cactus flower infusions for prostate and urological problems is documented across Latin American, Sicilian, and Korean folk medicine. Subjective BPH symptom improvements have been noted at 500 mg flower powder three times daily. No controlled prostate trials exist.
- soursopTraditional
There is documented traditional use of soursop for urinary tract conditions, and its cytotoxic acetogenins have been studied for activity against cancer cell lines including prostate-related lines in the broader anticancer literature, but specific prostate clinical or robust pre-clinical evidence is limited.
- squawvineTraditional
Traditional herbal sources document squawvine as a prostate tonic for men, analogous to its uterine-tonic role in women, with folk medicine applications for BPH-related urinary symptoms. No clinical evidence exists.